Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery

Purpose To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery. Methods This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eye 2000-10, Vol.14 (5), p.757-760
Hauptverfasser: Rainer, Georg, Menapace, Rupert, Findl, Oliver, Georgopoulos, Michael, Kiss, Barbara, Heinze, Georg
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 760
container_issue 5
container_start_page 757
container_title Eye
container_volume 14
creator Rainer, Georg
Menapace, Rupert
Findl, Oliver
Georgopoulos, Michael
Kiss, Barbara
Heinze, Georg
description Purpose To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery. Methods This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively. Results The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg; p = 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p < 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group ( p = 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups. Conclusions 2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.
doi_str_mv 10.1038/eye.2000.198
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72491160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72491160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</originalsourceid><addsrcrecordid>eNp1kU9rFjEQh4Mo9m315lkCQk9unWT_5ijFWqFQEAVvSzaZtCm7yZrsKm-_i9_VWd6XejKXIckzv4FnGHsj4EJA2X3APV5IALqp7hnbibpWRQuiec52oGoopJQ_Tthpzg8AompbeMlOBJ2mUWrH_nzVwcbJZ7Tc4TjG35wCuYnTrJPPMfDo-HKPHJ1Ds_hfGDDn7dHG9BhHPXmLnDK4npM2Ywze-oCcGn1Yko5mHXXic6KuNSF3cZvhwx2f77WJOK1j9s4bvXhqoaIpZeHE3mHav2IvnB4zvj7WM_b96tO3y-vi5vbzl8uPN4WpRLMUaKHpBihrZwfZQCntYCtZCjXUdFXQViV0yolOtk7XdVk3IAQIBAmtagdbnrHzQ-6c4s8V89KTEUM6dMC45r6VlSJjQOD7A2hSzDmh6-fkJ532vYB-W0dP9vptHT2tg_C3x9x1mND-g4_-CXh3BHQ2enRJB-PzE9dRopJEFQcq00cgMf1DXFMgI_8byw980AtJf4ojaGM25C9I6rAV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72491160</pqid></control><display><type>article</type><title>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SAGE Complete A-Z List</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rainer, Georg ; Menapace, Rupert ; Findl, Oliver ; Georgopoulos, Michael ; Kiss, Barbara ; Heinze, Georg</creator><creatorcontrib>Rainer, Georg ; Menapace, Rupert ; Findl, Oliver ; Georgopoulos, Michael ; Kiss, Barbara ; Heinze, Georg</creatorcontrib><description>Purpose To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery. Methods This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively. Results The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg; p = 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p &lt; 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group ( p = 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups. Conclusions 2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1559-7016</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2000.198</identifier><identifier>PMID: 11116699</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adrenergic alpha-Agonists - therapeutic use ; Aged ; Aged, 80 and over ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Carbonic Anhydrase Inhibitors - therapeutic use ; clinical-study ; Clonidine - analogs &amp; derivatives ; Clonidine - therapeutic use ; Eye ; Female ; Humans ; Laboratory Medicine ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Ocular Hypertension - etiology ; Ocular Hypertension - prevention &amp; control ; Ophthalmology ; Phacoemulsification - adverse effects ; Pharmaceutical Sciences/Technology ; Pharmacology. Drug treatments ; Prospective Studies ; Sulfonamides - therapeutic use ; Surgery ; Surgical Oncology ; Thiophenes - therapeutic use</subject><ispartof>Eye, 2000-10, Vol.14 (5), p.757-760</ispartof><rights>College of Ophthalmologists 2000</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</citedby><cites>FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/eye.2000.198$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/eye.2000.198$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=803892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11116699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rainer, Georg</creatorcontrib><creatorcontrib>Menapace, Rupert</creatorcontrib><creatorcontrib>Findl, Oliver</creatorcontrib><creatorcontrib>Georgopoulos, Michael</creatorcontrib><creatorcontrib>Kiss, Barbara</creatorcontrib><creatorcontrib>Heinze, Georg</creatorcontrib><title>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</title><title>Eye</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Purpose To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery. Methods This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively. Results The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg; p = 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p &lt; 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group ( p = 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups. Conclusions 2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.</description><subject>Adrenergic alpha-Agonists - therapeutic use</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carbonic Anhydrase Inhibitors - therapeutic use</subject><subject>clinical-study</subject><subject>Clonidine - analogs &amp; derivatives</subject><subject>Clonidine - therapeutic use</subject><subject>Eye</subject><subject>Female</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - etiology</subject><subject>Ocular Hypertension - prevention &amp; control</subject><subject>Ophthalmology</subject><subject>Phacoemulsification - adverse effects</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Sulfonamides - therapeutic use</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Thiophenes - therapeutic use</subject><issn>0950-222X</issn><issn>1559-7016</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9rFjEQh4Mo9m315lkCQk9unWT_5ijFWqFQEAVvSzaZtCm7yZrsKm-_i9_VWd6XejKXIckzv4FnGHsj4EJA2X3APV5IALqp7hnbibpWRQuiec52oGoopJQ_Tthpzg8AompbeMlOBJ2mUWrH_nzVwcbJZ7Tc4TjG35wCuYnTrJPPMfDo-HKPHJ1Ds_hfGDDn7dHG9BhHPXmLnDK4npM2Ywze-oCcGn1Yko5mHXXic6KuNSF3cZvhwx2f77WJOK1j9s4bvXhqoaIpZeHE3mHav2IvnB4zvj7WM_b96tO3y-vi5vbzl8uPN4WpRLMUaKHpBihrZwfZQCntYCtZCjXUdFXQViV0yolOtk7XdVk3IAQIBAmtagdbnrHzQ-6c4s8V89KTEUM6dMC45r6VlSJjQOD7A2hSzDmh6-fkJ532vYB-W0dP9vptHT2tg_C3x9x1mND-g4_-CXh3BHQ2enRJB-PzE9dRopJEFQcq00cgMf1DXFMgI_8byw980AtJf4ojaGM25C9I6rAV</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>Rainer, Georg</creator><creator>Menapace, Rupert</creator><creator>Findl, Oliver</creator><creator>Georgopoulos, Michael</creator><creator>Kiss, Barbara</creator><creator>Heinze, Georg</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</title><author>Rainer, Georg ; Menapace, Rupert ; Findl, Oliver ; Georgopoulos, Michael ; Kiss, Barbara ; Heinze, Georg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-ed068b035fdb26032dbd42319b526090743089f1827fa5535601101e020797bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adrenergic alpha-Agonists - therapeutic use</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carbonic Anhydrase Inhibitors - therapeutic use</topic><topic>clinical-study</topic><topic>Clonidine - analogs &amp; derivatives</topic><topic>Clonidine - therapeutic use</topic><topic>Eye</topic><topic>Female</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - etiology</topic><topic>Ocular Hypertension - prevention &amp; control</topic><topic>Ophthalmology</topic><topic>Phacoemulsification - adverse effects</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Sulfonamides - therapeutic use</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Thiophenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rainer, Georg</creatorcontrib><creatorcontrib>Menapace, Rupert</creatorcontrib><creatorcontrib>Findl, Oliver</creatorcontrib><creatorcontrib>Georgopoulos, Michael</creatorcontrib><creatorcontrib>Kiss, Barbara</creatorcontrib><creatorcontrib>Heinze, Georg</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Eye</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rainer, Georg</au><au>Menapace, Rupert</au><au>Findl, Oliver</au><au>Georgopoulos, Michael</au><au>Kiss, Barbara</au><au>Heinze, Georg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery</atitle><jtitle>Eye</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>14</volume><issue>5</issue><spage>757</spage><epage>760</epage><pages>757-760</pages><issn>0950-222X</issn><eissn>1559-7016</eissn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Purpose To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (lOP) following phacoemulsification cataract surgery. Methods This prospective, randomised study comprised 54 eyes of 27 consecutive patients with age-related cataract scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0 mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The lOP was measured pre- operatively as well as 6 h and 20-24 h and 1 week post-operatively. Results The mean pre-operative lOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg; p = 0.450). At 6 h post-operatively, the mean lOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg vs 18.0 ± 4.0 mmHg; p &lt; 0.001). An lOP increase of more than 5 mmHg at 6 h post-operatively occurred in 3 (12%) eyes in the dorzolamide group and in 9 (36%) eyes in the apraclonidine group ( p = 0.034). At 20-24 h post-operatively and at 1 week post-operatively no difference was found between the groups. Conclusions 2% Dorzolamide is more effective than 0.5% apraclonidine in preventing the early post-operative lOP increase following phacoemulsification cataract surgery.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11116699</pmid><doi>10.1038/eye.2000.198</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-222X
ispartof Eye, 2000-10, Vol.14 (5), p.757-760
issn 0950-222X
1559-7016
1476-5454
language eng
recordid cdi_proquest_miscellaneous_72491160
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SAGE Complete A-Z List; SpringerLink Journals - AutoHoldings
subjects Adrenergic alpha-Agonists - therapeutic use
Aged
Aged, 80 and over
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Carbonic Anhydrase Inhibitors - therapeutic use
clinical-study
Clonidine - analogs & derivatives
Clonidine - therapeutic use
Eye
Female
Humans
Laboratory Medicine
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Ocular Hypertension - etiology
Ocular Hypertension - prevention & control
Ophthalmology
Phacoemulsification - adverse effects
Pharmaceutical Sciences/Technology
Pharmacology. Drug treatments
Prospective Studies
Sulfonamides - therapeutic use
Surgery
Surgical Oncology
Thiophenes - therapeutic use
title Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A26%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomised%20fellow%20eye%20comparison%20of%20the%20effectiveness%20of%20dorzolamide%20and%20apraclonidine%20on%20intraocular%20pressure%20following%20phacoemulsification%20cataract%20surgery&rft.jtitle=Eye&rft.au=Rainer,%20Georg&rft.date=2000-10-01&rft.volume=14&rft.issue=5&rft.spage=757&rft.epage=760&rft.pages=757-760&rft.issn=0950-222X&rft.eissn=1559-7016&rft.coden=EYEEEC&rft_id=info:doi/10.1038/eye.2000.198&rft_dat=%3Cproquest_cross%3E72491160%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72491160&rft_id=info:pmid/11116699&rfr_iscdi=true